肝切除术后肝细胞癌侵袭性复发的组织学预测因素
回顾性纳入2000年2月至2020年11月单发肝细胞癌(BCLC-0/A)行肝切除患者218例,中位随访49个月,58%复发,侵袭性复发占35%,5年生存率81%;微血管侵犯和/或卫星结节是复发、侵袭性复发和死亡的唯一独立预测因素。
要点
- 微血管侵犯和/或卫星结节是复发、侵袭性复发和死亡的唯一独立预测因素。
- 侵袭性复发定义为首次复发时超出米兰标准,占复发患者的35%。
- 大梁状巨块型与微血管侵犯和/或卫星结节、Edmondson-Steiner III-IV级等相关,但与复发无关。
核心结论
- 微血管侵犯和/或卫星结节的存在是侵袭性复发和死亡的唯一独立危险因素。
- 这对早期患者管理具有重要意义,尤其在辅助免疫治疗或初始肝移植的背景下。
研究设计与样本
- 回顾性研究,纳入2000年2月至2020年11月期间接受肝切除术的所有单发肝细胞癌(BCLC-0/A)患者。
- 共纳入218例患者(30% BCLC 0,70% BCLC A),中位(IQR)肿瘤大小28(19-42 mm)。
- 组织学特征由两名独立病理学家盲法评估。
主要发现
- 微血管侵犯和/或卫星结节的患病率为39%,两名病理学家间的kappa指数为0.8。
- 中位随访49(23-85)个月后,61/218(28%)患者死亡,32/218(15%)接受肝移植,127例(58%)出现肝细胞癌复发。
- 侵袭性复发患病率为35%(44/127例超出米兰标准,其中20例为晚期),5年生存率为81%。
- 微血管侵犯和/或卫星结节是复发的唯一独立预测因素(HR 1.83,95%CI 1.28-2.61,p<0.001)。
- 微血管侵犯和/或卫星结节是侵袭性复发的唯一独立预测因素(HR 3.31,95%CI 1.74-6.29,p<0.001)。
关键数值与推荐
- 侵袭性复发定义为首次复发时超出米兰标准。
- 大梁状巨块型与微血管侵犯和/或卫星结节、Edmondson-Steiner III-IV级、甲胎蛋白值和血管包绕肿瘤簇的更高患病率显著相关,但与复发、侵袭性复发或总生存无关。
临床怎么用
- 复发高风险患者是初始肝移植适应症或潜在辅助治疗的候选者。
- 微血管侵犯和/或卫星结节的存在可用于指导治疗管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Assessment of recurrence risk after liver resection (LR) is critical in hepatocellular carcinoma (HCC), particularly with the advent of effective adjuvant therapy. The aim of this study was to analyze the clinical and pathological factors associated with recurrence, aggressive recurrence, and survival after LR. METHOD: We performed a retrospective study in which all single HCC (BCLC-0/A) patients treated with LR between February 2000 and November 2020 were included. The main clinical variables were recorded. Histological features were blindly evaluated by two independent pathologists. Aggressive recurrence was defined as those that exceeded the Milan criteria at 1st recurrence. RESULTS: A total of 218 patients were included (30% BCLC 0 and 70% BCLC A), median (IQR) tumor size of 28 (19-42 mm). The prevalence of microvascular invasion and/or satellitosis (mVI/S) was 39%, with a kappa-index between both pathologists of 0.8. After a median follow-up of 49 (23-85) months, 61/218 (28%) patients died, 32/218 (15%) underwent liver transplantation, 127 (58%) developed HCC recurrence. The prevalence of aggressive recurrence was 35% (44/127 Milan-out, with 20 cases at advanced stage), and the 5-year survival rate was 81%. The presence of mVI/S was the only independent predictor of recurrence (hazard ratio [HR] 1.83, 95% CI 1.28-2.61, p <0.001), aggressive recurrence (HR 3.31, 95% CI 1.74-6.29, p <0.001) and mortality (HR 2.23, 95% CI 1.27-3.91, p = 0.005). The macrotrabecular-massive subtype was significantly associated with a higher prevalence of mVI/S, Edmonson Steiner grade III-IV, AFP values and vessels that encapsulate tumor clusters, but not with recurrence, aggressive recurrence, or overall survival. CONCLUSION: The presence of mVI/S was the only independent risk factor for aggressive recurrence and mortality. This has important implications for early-stage patient management, especially in the setting of adjuvant immunotherapy or ab initio LT. IMPACT AND IMPLICATIONS: Assessment of recurrence risk after liver resection is crucial in patients with hepatocellular carcinoma. Patients with a high risk of recurrence are candidates for liver transplantation as an ab initio indication or for the potential use of adjuvant therapy. Aggressive recurrences, defined as those exceeding the Milan criteria at first recurrence, have a significant impact on overall survival (OS). Fifty-eight percent of patients experienced hepatocellular carcinoma recurrence, with a prevalence of aggressive recurrence at the first occurrence standing at 35%. After a median follow-up of 49 (23-85) months, 61 (28%) patients died, and 32 (15%) underwent liver transplantation, resulting in a 5-year OS rate of 81%. Microvascular invasion and/or satellitosis was present in 39% of our cohort and was the only independent predictor of recurrence, aggressive recurrence, and OS on multivariate analysis. This is important as it could be used to guide therapeutic management.
引用
- Fuster-Anglada C, Mauro E, Ferrer-Fàbrega J, et al. Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol. 2024. PMID: 38925272. doi:10.1016/j.jhep.2024.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。